| Ashley Adams, MA, CCC-SLP | |
|
610 Campus Dr, Abingdon, VA 24210-2589 | |
| (276) 619-2405 | |
| Not Available |
| Full Name | Ashley Adams |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 610 Campus Dr, Abingdon, Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093904039 | NPI | - | NPPES |
| 2202004063 | Other | VA | VA DEPT OF HEALTH PROFESS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 2202004063 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ashley Adams, MA, CCC-SLP 610 Campus Dr, Abingdon, VA 24210-2589 Ph: (276) 619-2405 | Ashley Adams, MA, CCC-SLP 610 Campus Dr, Abingdon, VA 24210-2589 Ph: (276) 619-2405 |
News Archive
Abbott today announced that it has initiated the ABSORB Japan randomized controlled clinical trial to evaluate the Absorb Bioresorbable Vascular Scaffold in patients with coronary artery disease, the most common form of heart disease.
A new modeling study by the University of Louisville School of Public Health and Information Sciences and the Louisville Metro Department of Public Health & Wellness (LMPHW) indicates that stringent social distancing measures the city put in place in March have significantly slowed the spread of COVID-19 in the city.
CTI BioPharma Corp. today announced data showing treatment with pacritinib, an investigational oral multikinase inhibitor in Phase 3 clinical development, preferentially killed acute myeloid leukemia (AML) cells with FLT3 mutations, overcame stromal protection and suppressed leukemic outgrowth from stroma adherent AML cells in both medium-term (7-14 days) and long-term (5-6 weeks) assays.
The "mutational burden," or the number of mutations present in a tumor's DNA, is a good predictor of whether that cancer type will respond to a class of cancer immunotherapy drugs known as checkpoint inhibitors, a new study led by Johns Hopkins Kimmel Cancer Center researchers shows.
U.S. cancer survivors face significant economic burdens due to growing medical costs, missed work, and reduced productivity, according to a study by the Centers for Disease Control and Prevention in today's Morbidity and Mortality Weekly Report.
› Verified 2 days ago
Meagan R Compton, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 18596 Lee Hwy Suite B, Abingdon, VA 24210 Phone: 276-525-6043 | |
Victoria Lenore Blevins, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 347 Oakland St Sw, Abingdon, VA 24210 Phone: 571-225-1908 | |
Kathryn Elizabeth Hurley, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 15051 Harmony Hills Ln, Abingdon, VA 24211 Phone: 276-451-2590 | |
Highlands Speech Therapy, Llc Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 26062 Cornelius Dr, Abingdon, VA 24211 Phone: 276-365-8615 | |
Ms. Elizabeth Ann Crews, MA, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 196 Hillside Dr Ne, Abingdon, VA 24210 Phone: 828-755-7520 | |
Speech Geek, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 851 French Moore Jr Blvd, Suite 193, Abingdon, VA 24210 Phone: 276-492-2069 Fax: 865-381-1275 |